The U.S. Food and Drug Administration has granted 510(k) clearance to Takeda's HyHub and HyHub Duo devices, marking a significant advancement in at-home immunoglobulin therapy administration. The devices are designed to simplify the infusion process for HYQVIA, enabling patients aged 17 and older to transfer the therapy's dual-vial components without using needles.
Streamlined Administration Process
HyHub and HyHub Duo serve as docking stations for the dual vial units (DVUs) used in HYQVIA administration, which consists of one vial of immunoglobulin and one vial of recombinant human hyaluronidase. The devices significantly reduce the complexity of preparation compared to traditional methods.
According to Takeda, HyHub can reduce preparation steps by up to 50% when using four dual-vial units, while HyHub Duo cuts steps by approximately one-third for two DVUs. Both devices also minimize the need for ancillary supplies during infusion preparation and come with a dedicated carrier bag to aid mobility during the infusion process.
"This milestone exemplifies our dedication to advancing innovative solutions that can enhance the treatment administration experience for people who rely on infusions of facilitated immunoglobulin like HYQVIA," said Kristina Allikmets, senior vice president and head of Research & Development for Takeda's Plasma-Derived Therapies Business Unit. "We designed HyHub and HyHub Duo, Takeda's first customized devices for use with a plasma-derived therapy, with input from patients and caregivers."
HYQVIA Treatment Applications
HYQVIA is approved for use in adults and children as young as two years old with primary immunodeficiency (PI), and in adults as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). The drug can be administered as infrequently as once a month.
The CIDP approval was based on findings from the randomized, double-blinded, placebo-controlled ADVANCE-CIDP 1 trial and the single-arm, open-label, extension ADVANCE-CIDP 3 study. In the primary trial among 122 patients, the relapse rates showed a statistical difference between the HYQVIA group (14.0%) compared with the placebo group (32.3%), which was significant (P = .0314). The treatment difference of -18.3% indicated that HYQVIA displayed superiority over placebo in preventing relapse of CIDP.
Patient Impact and Availability
The clearance addresses a critical need for patients requiring long-term immunoglobulin therapy. "For people living with primary immunodeficiency, innovative devices that can help simplify the administration process of their immunoglobulin treatment can be especially meaningful as many require lifelong treatment for their disease," said Jorey Berry, president and CEO of the Immune Deficiency Foundation.
Takeda plans to make the devices available at no additional cost to patients starting in the second half of fiscal year 2025. The company has also submitted a CE Mark application for the devices in the European Union during the first quarter of fiscal year 2025 and will assess making them available in other markets in the future.
Safety Profile
The safety of HYQVIA in adults with CIDP was assessed across participants in ADVANCE-CIDP 1 and ADVANCE-CIDP 3 studies. The most common adverse effects observed in at least 5% of study participants included local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and pain in extremity.
The devices are intended for use only with HYQVIA and represent part of a broader trend toward patient-friendly innovations in immunoglobulin therapy administration, potentially improving quality of life for patients requiring lifelong treatment.
